ReportsnReports – Global Clinical Trials Market (2007 – 2010)
Global Clinical Trials Market (2007 – 2010)ReportsnReports.com adds MarketsandMarkets Market Research Report “Global ClinicalTrials Market (2007 – 2010)’’ to its store.Clinical trials market now witnesses a paradigm shift. Naïve heterogeneous patientpopulations in the developing nations are opening up new avenues for the clinical trialsmarket. Developing countries also offer faster means; which is triggering majorpharmaceutical companies to direct their investment in these regions. Apart from this,stringent regulations and tight R&D budgets in the pharma-biotech industry are also forcingcompanies to move to east. This scenario has further boosted the alliances between thepharma-biotech companies and the clinical research organizations, with the latteraccounting for major chunk of the trials conducted.Today, emerging countries account for the largest share of the phase II/III (prime stages)clinical trials conducted globally with major focus on oncology, Alzheimer’s, metabolic, andcardiovascular diseases. Support from the respective government bodies is one of the majorfactors affecting the clinical trials market. Clinical trials sponsored by the industry have amuch higher share in the market as compared to government organizations.North America includes the U.S. and Canada; together both the countries have reported tohave the largest number of clinical trials conducted globally. In the European region,Germany heads the largest number of clinical trials, the country was reported to haveconducted 734 trials for 2010 in Western Europe while Poland accounted for the largestnumber of clinical trials in Eastern Europe with total number of 263 clinical trials for 2010.Asia is one of the fastest growing markets for global clinical trials. The countries taking leadin this market are India, China, South Korea, and Singapore. The major reasons for thismarket to have high potential are its huge and diverse population with diseases that arepresent in both – the developed and under developed countries. Hence, different types oftrials can be conducted in one region. Due to large population, it helps in faster recruitmentof the patients, and retention of the participants in the trials on the higher side; therebyhelping the companies to conduct the trials on the timely basis.The financial targets and global competition are forcing the pharmaceutical players to lookout for various options to introduce novel therapies in the market. At the same time,emerging shortage of clinical resources such as lack of naïve disease population, welltrained labor, and sound medical infrastructure are delaying the process to initiate trials.Hence, all these companies are considering Latin America as an alternative option forconducting clinical trials.The key players (Clinical Research Organizations) in the market include Chiltern, Omnicare,PPD, Parexel, Kendle, and Quintles.The global clinical trials conducted in 2008 were reported to be 10,326 and were highestfrom 2007 to 2010. Oncology trials were the most widely conducted clinical trials accounting
for 28.47% of all the trials conducted for the year 2008. Asia reported to a steady growth ascompared to the other regions; which showed decline in the total number of clinical trials inthe year 2010.Scope of the reportGlobal clinical trials market research report categorizes by phases, by the study design, bythe disease indications and with analysis of the geographic trends of conducting the clinicaltrials.Clinical trials market by phases: Phase I Phase II Phase IIIClinical trials market by study design Interventional trials Observational trials Expanded Access trials.Clinical trials market by indications Autoimmune Blood disorders Cancer Circulatory CNS Congenital CVS Dermatology Ear Gastrointestinal Genitourinary Infections Mental disorders Metabolic Musculoskeletal Nose Ophthalmology Others Clinical trials on basis of geography: North America South America Asia EuropeEach section of the report provides market tables for covering the number of clinical trialsconducted between 2007 and 2010.In addition, the report also provides 19 company profiles of the CROs covering the servicesand geographic presence.
TABLE OF CONTENTS1 INTRODUCTION1.1 KEY TAKE-AWAYS1.2 REPORT DESCRIPTION1.3 MARKETS COVERED1.4 STAKEHOLDERS1.5 RESEARCH METHODOLOGY2 EXECUTIVE SUMMARY2.1 OVERVIEW OF THE MARKET2.2 KEY FINDINGS3 MARKET OVERVIEW3.1 MARKET DEFINITION3.2 DRIVERS3.2.1 GLOBALIZING DRUG DEVELOPMENT ACTIVITIES3.2.2 RISE IN R&D INVESTMENTS EXPECTED TO BOOST THE CLINICAL TRIALS MARKET3.2.3 HIGH DISEASE PREVALENCE IN EMERGING COUNTRIES3.3 RESTRAINTS3.3.1 LONGER APPROVAL TIME FOR CLINICAL TRIALS – A CAUSE OF CONCERN FOR MAJORPHARMACEUTICAL-BIOTECHNOLOGY PLAYERS3.4 BURNING ISSUES3.4.1 OUT SKIRTING BOUNDARIES OF MEDICAL ETHICS3.5 WINNING IMPERATIVES3.5.1 LEVERAGING ONLINE RESOURCES TO INCREASE PATIENT RECRUITMENT RATES INCLINICAL TRIALS3.6 COUNTRY COMPARISON3.7 INDUSTRY TRENDS3.7.1 ENGAGING CLINICAL TRIALS IN EMERGING COUNTRIES & LOW COST CRO’S PROVETO BE COMPELLING OPTIONS IN TIMES OF DRUG PATENT EXPIRY3.7.2 CROS LEVERAGING THE BENEFITS OF EMERGING MARKETS3.7.3 CHANGING CRO BUSINESS MODELS126.96.36.199 Full service model188.8.131.52 Hourly billing model184.108.40.206 Full time equivalent model (FTE)220.127.116.11 Fixed price model3.7.4 PREVALENCE OF PREFERRED PROVIDER RELATIONSHIPS3.7.5 SHIFT TOWARDS PATIENT CENTRIC CLINICAL TRIALS DUE TO TECHNICAL ADVANCES3.8 GLOBAL CLINICAL TRIALS MARKET3.8.1 OFFSHORING & OUTSOURCING4 CLINICAL TRIALS MARKET, BY TYPES4.1 INTRODUCTION4.1.1 CLINICAL TRIALS MARKET, BY STUDY PHASES18.104.22.168 Preclinical studies22.214.171.124 Phase I trials126.96.36.199 Phase II trials188.8.131.52 Phase I/II
184.108.40.206 Phase II/III220.127.116.11 Phase III trials4.1.2 CLINICAL TRIALS MARKET, BY STUDY DESIGNS18.104.22.168 Observational studies22.214.171.124 Interventional studies126.96.36.199 Expanded Access Trials4.1.3 CLINICAL TRIALS MARKET, BY INDICATIONS5 GEOGRAPHIC ANALYSIS5.1 NORTH AMERICA5.1.1 U.S.188.8.131.52 Regulatory environment184.108.40.206 Clinical trials registry220.127.116.11 Government support5.1.2 CANADA18.104.22.168 Regulatory environment22.214.171.124 Clinical trials registry126.96.36.199 Government support5.2 EUROPE5.2.1 UK188.8.131.52 Regulatory environment184.108.40.206 Clinical trials registry220.127.116.11 Government support5.2.2 GERMANY18.104.22.168 Regulatory environment22.214.171.124 Clinical trials registry126.96.36.199 Government support5.2.3 ITALY188.8.131.52 Regulatory environment184.108.40.206 Clinical trials registry220.127.116.11 Government support5.2.4 FRANCE18.104.22.168 Regulatory environment22.214.171.124 Clinical trials registry126.96.36.199 Support rendered by the government5.2.5 SPAIN188.8.131.52 Regulatory environment184.108.40.206 Clinical trials registry220.127.116.11 Government support5.2.6 POLAND18.104.22.168 Regulatory environment22.214.171.124 Clinical trials registry126.96.36.199 Support rendered by the Government5.2.7 RUSSIA188.8.131.52 Regulatory environment184.108.40.206 Clinical trials registry220.127.116.11 Support rendered by the Government5.2.8 TURKEY18.104.22.168 Regulatory environment
22.214.171.124 Clinical trials registry126.96.36.199 Government support5.2.9 UKRAINE188.8.131.52 Regulatory environment184.108.40.206 Clinical trials registry220.127.116.11 Support rendered by the Government5.3 ASIA5.3.1 CHINA18.104.22.168 Clinical trials registry22.214.171.124 Government support5.3.2 INDIA126.96.36.199 Regulatory environment188.8.131.52 Clinical trials registry184.108.40.206 Government support5.3.3 SOUTH KOREA220.127.116.11 Regulatory environment18.104.22.168 Clinical trials registry22.214.171.124 Government support5.4 LATIN AMERICA5.4.1 BRAZIL126.96.36.199 Regulatory environment188.8.131.52 Clinical trials registry184.108.40.206 Government support5.4.2 MEXICO220.127.116.11 Regulatory environment18.104.22.168 Clinical trials registry22.214.171.124 Government support5.4.3 ARGENTINA126.96.36.199 Regulatory environment188.8.131.52 Clinical trials registry184.108.40.206 Government support6 COMPETITIVE LANDSCAPE6.1 INTRODUCTION7 COMPANY PROFILES7.1 AAIPHARMA SERVICES CORP.7.1.1 OVERVIEW7.1.2 FINANCIALS7.1.3 PRODUCTS & SERVICES7.1.4 STRATEGY7.1.5 DEVELOPMENTS7.2 ACCELL CLINICAL RESEARCH LLC7.2.1 OVERVIEW7.2.2 FINANCIALS7.2.3 PRODUCTS & SERVICES7.2.4 STRATEGY7.2.5 DEVELOPMENTS7.3 APTIV SOLUTIONS